647 related articles for article (PubMed ID: 19636013)
1. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
[TBL] [Abstract][Full Text] [Related]
2. Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
[TBL] [Abstract][Full Text] [Related]
3. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
Kerr KW; Glos LJ
Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
[TBL] [Abstract][Full Text] [Related]
5. US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018.
Omae K; Onishi A; Sahker E; Furukawa TA
JAMA Netw Open; 2022 Sep; 5(9):e2230973. PubMed ID: 36083581
[TBL] [Abstract][Full Text] [Related]
6. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
7. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval.
Liu ITT; Kesselheim AS; Cliff ERS
JAMA; 2024 May; 331(17):1471-1479. PubMed ID: 38583175
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.
Naci H; Smalley KR; Kesselheim AS
JAMA; 2017 Aug; 318(7):626-636. PubMed ID: 28810023
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
Kesselheim AS; Myers JA; Avorn J
JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
[TBL] [Abstract][Full Text] [Related]
10. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
Nakayama H; Matsumaru N; Tsukamoto K
Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
[TBL] [Abstract][Full Text] [Related]
11. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review.
Beaver JA; Howie LJ; Pelosof L; Kim T; Liu J; Goldberg KB; Sridhara R; Blumenthal GM; Farrell AT; Keegan P; Pazdur R; Kluetz PG
JAMA Oncol; 2018 Jun; 4(6):849-856. PubMed ID: 29494733
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
[TBL] [Abstract][Full Text] [Related]
13. Incentives for orphan drug research and development in the United States.
Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Visaria J
Orphanet J Rare Dis; 2008 Dec; 3():33. PubMed ID: 19087348
[TBL] [Abstract][Full Text] [Related]
14. End points and United States Food and Drug Administration approval of oncology drugs.
Johnson JR; Williams G; Pazdur R
J Clin Oncol; 2003 Apr; 21(7):1404-11. PubMed ID: 12663734
[TBL] [Abstract][Full Text] [Related]
15. Increasing FDA-accelerated approval of single-arm trials in oncology (1992 to 2020).
Ribeiro TB; Bennett CL; Colunga-Lozano LE; Araujo APV; Hozo I; Djulbegovic B
J Clin Epidemiol; 2023 Jul; 159():151-158. PubMed ID: 37037322
[TBL] [Abstract][Full Text] [Related]
16. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
[TBL] [Abstract][Full Text] [Related]
17. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
Michaeli T; Jürges H; Michaeli DT
BMJ; 2023 May; 381():e073242. PubMed ID: 37160306
[TBL] [Abstract][Full Text] [Related]
18. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of Anticancer Drugs Approved Under the Accelerated Approval Program in the US: Success or Failure in Converting to Regular Approval.
Oda Y; Narukawa M
Ther Innov Regul Sci; 2024 Mar; 58(2):387-394. PubMed ID: 38175382
[TBL] [Abstract][Full Text] [Related]
20. 2016 in review: FDA approvals of new molecular entities.
Griesenauer RH; Kinch MS
Drug Discov Today; 2017 Nov; 22(11):1593-1597. PubMed ID: 28687460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]